CD1a-restricted T-cell receptor

Applications: TCR-based immunotherapy, bispecific TCR therapeutics, cancer diagnostics, inflammation biomarkers, immune monitoring, CD1a-targeted drug development

Identification of CD1a-reactive T cell receptors, including a shared alpha chain sequence found across multiple donors. This discovery enables new approaches to detect, study, and therapeutically target CD1a-expressing cells in cancer and inflammatory diseases.

Features	Benefits
Function confirmed by TCR transfer via CRISPR HDR into cells with CD1a-specific activation	Broad applicability across inflammatory skin and mucosal conditions and CD1a-expressing malignancies
Invariant CD1a-reactive TCR alpha chain across donors	Therapeutic potential: Enables TCR-T and bispecific therapies targeting CD1a, with a particular relevance to skin inflammation, as well as subsets of lymphoma and other CD1a-expressing cancers
Conserved core motif with defined CDR1/2 patterns useful for engineering	Diagnostic utility: Shared TCRs serve as biomarkers for CD1a-reactive T cells
Extensive functional validation of TCRs, including via transfer into recipient T cells	Research advancement: Faster lead discovery and optimisation using the shared motif and defined sequence templates
Novel robust isolation and expansion workflow using CD1a multimers, cytokine capture, single-cell cloning	High functional avidity and mechanism validated in transfer assays, de-risking translation
Sequence-resolved panel of alpha/beta TCRs with specified CDRs and V/J usage

Related Publication: CD1a promotes systemic manifestations of skin inflammation | Nature Communications https://doi.org/10.1038/s41467-022-35071-1

Request more information
about this technology

Back to Technologies Available

Technologies for License

CD1a-restricted T-cell receptor

Ready to get in touch?